deferasirox has been researched along with methotrexate in 5 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (methotrexate) | Trials (methotrexate) | Recent Studies (post-2010) (methotrexate) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 41,593 | 5,666 | 11,969 |
| Protein | Taxonomy | deferasirox (IC50) | methotrexate (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.8 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 0.211 | |
| Toll-like receptor 4 | Homo sapiens (human) | 1.04 | |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | 0.08 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0522 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.0331 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0348 | |
| Dihydrofolate reductase | Gallus gallus (chicken) | 0.0545 | |
| Dihydrofolate reductase | Enterococcus faecium | 0.0014 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0138 | |
| Thymidylate synthase | Homo sapiens (human) | 0.343 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0147 | |
| Thymidylate synthase | Escherichia coli K-12 | 0.0181 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1529 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.084 | |
| Folate receptor beta | Homo sapiens (human) | 0.1585 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0011 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.0012 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2263 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0717 | |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | 0.0014 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.01 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.01 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Reduced folate transporter | Homo sapiens (human) | 0.012 | |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | 0.0174 | |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | 3.2 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0547 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.11 | |
| Dihydrofolate reductase | Bacillus anthracis | 0.0136 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0047 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.1207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abedi, M; Esmaeili, A; Rahgozar, S | 1 |
1 review(s) available for deferasirox and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for deferasirox and methotrexate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity.
Topics: Acetylcysteine; Bone Marrow; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Deferasirox; Drug Resistance, Neoplasm; Female; Ferric Compounds; Free Radical Scavengers; Humans; Infant; Inhibitory Concentration 50; Iron; Iron Chelating Agents; Male; Methotrexate; Multidrug Resistance-Associated Proteins; NF-E2-Related Factor 2; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Quaternary Ammonium Compounds; Reactive Oxygen Species; RNA, Messenger; Superoxide Dismutase; Transcriptome; Up-Regulation | 2020 |